6개월 단기 항결핵 화학요법의 성적

Results of 6 Month Short Course Chemotherpay for Pulmonary Tuberculosis with 2SHRZ/4HR

  • 이향주 (중앙대학교 의과대학 내과학교실) ;
  • 민철홍 (중앙대학교 의과대학 내과학교실) ;
  • 이선우 (중앙대학교 의과대학 내과학교실) ;
  • 박인원 (중앙대학교 의과대학 내과학교실) ;
  • 최병휘 (중앙대학교 의과대학 내과학교실) ;
  • 허성호 (중앙대학교 의과대학 내과학교실)
  • Lee, Hyang-Ju (Department of Internal Medicine, College of Medicine, Chung Ang University) ;
  • Min, Chul-Hong (Department of Internal Medicine, College of Medicine, Chung Ang University) ;
  • Lee, Sun-Woo (Department of Internal Medicine, College of Medicine, Chung Ang University) ;
  • Park, In-Won (Department of Internal Medicine, College of Medicine, Chung Ang University) ;
  • Choi, Byoung-Whui (Department of Internal Medicine, College of Medicine, Chung Ang University) ;
  • Hue, Sung-Ho (Department of Internal Medicine, College of Medicine, Chung Ang University)
  • 발행 : 1991.06.30

초록

A clinical trial was made on 76 patients with pulmonary tuberculosis to determine the effectiveness and acceptibility of 6 month 2SHRZ/4HR antituberculosis regimen. Out of 76 patients, 13 patients (17.1%) dropped out and 11 patients (14.5%) were excluded due to drug resistance. In 3 patients (3.9%), regimen was changed due to adverse effects. Treatment failure rate was 2.0% in 50 patients. One patient, who had far advanced lesion, was treated longer than 6 months due to failure of sputum conversion. The most common adverse effect was arthralgia, which was controlled by the administration of allopurinol and nonsteroidal anti-inflammatory drug. In conclusion, 2SHRZ/4HR for 6 months was effective regimen in treating the newly-diagnosed patients with tuberculosis, but change of the regimen and duration might be carefully considered by the severity of the lesion and adverse effect of the drug But further study will be needed to evaluate not only the efficacy and efficiency of 6 month chemotherapy but also relapse rates.

키워드